Research Topics
| R BagatellSummaryAffiliation: University of Arizona Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatinRochelle Bagatell
Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Int J Cancer 113:179-88. 2005..Our findings suggest that Hsp90 inhibitors may prove useful either alone or as a component of multi-drug regimens in the treatment of neuroblastoma and osteosarcoma...- Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancerR Bagatell
Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
Clin Cancer Res 7:2076-84. 2001.... - Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cavaRochelle Bagatell
Department of Pediatrics and Steele Memorial Children s Research Center, Tucson, Arizona, USA
J Pediatr Hematol Oncol 24:397-400. 2002..In one patient a pulmonary embolus developed after initiation of cytotoxic therapy; the second patient was prophylactically anticoagulated and had no embolic event... - When children die: a seminar series for pediatric residentsRochelle Bagatell
Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
Pediatrics 110:348-53. 2002..Our goals were to assist residents in acquiring skills needed to care for children at the end of life and to increase their comfort level regarding critical aspects of caring for dying children... - Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell
Department of Pediatrics and Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
Clin Cancer Res 13:1783-8. 2007.... - The perfect storm: Torsades de Pointes in a child with leukemiaRochelle Bagatell
Department of Pediatrics, Section of Pediatric Hematology Oncology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA
Pediatr Blood Cancer 49:996-9. 2007..Although the patient suffered cardiac arrest, rapid recognition of TdP and prompt defibrillation resulted in an excellent outcome... - Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell
University of Arizona, Department of Pediatrics and Steele Children s Research Center, Tuscon, AZ, USA
J Clin Oncol 23:8819-27. 2005..The goal of Pediatric Oncology Group 9243 was to improve outcomes for children with intermediate-risk neuroblastoma (NB)... - Altered Hsp90 function in cancer: a unique therapeutic opportunityRochelle Bagatell
Department of Pediatrics and Hematology/Oncology, Arizona Health Sciences Center, Room 5341, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
Mol Cancer Ther 3:1021-30. 2004.... - Inhibition of oncogene expression using vector-generated RNA antisenseL Whitesell
Department of Pediatrics, University of Arizona, Tucson, Arizona 85724, USA
Methods 18:296-303. 1999..Lastly, using specific examples, the limitations and potential artifacts associated with antisense vector use in the study of tumorigenesis are discussed... - The stress response: implications for the clinical development of hsp90 inhibitorsLuke Whitesell
Steele Memorial Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
Curr Cancer Drug Targets 3:349-58. 2003..Lastly, stress response induction by Hsp90 inhibitors may have therapeutic benefits in non-neoplastic disorders such as heart disease, stroke and neurodegenerative diseases. These benefits are just beginning to be explored... 
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell
University of Arizona Health Sciences Center, Tucson, AZ, USA
J Clin Oncol 27:365-70. 2009..To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk Group (INRG) database were analyzed...- Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitorsJason Beliakoff
Steele Memorial Children's Research Center, University of Arizona, Tucson, Arizona 85724, USA
Clin Cancer Res 9:4961-71. 2003..In this context, combined treatment with 17AAG and Tam should be avoided because Tam may inhibit the ability of 17AAG to deplete the ER, potentially reducing its anticancer activity... 
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumorsR Bagatell
Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19066, USA
Clin Cancer Res 17:611-9. 2011....- Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcomaCaroline Laverdiere
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 98:832-40. 2003..CONCLUSIONS: ET-743 was found to be well tolerated in heavily pretreated osteosarcoma patients but had limited antitumor activity as a single agent. The combination of ET-743 with cisplatin or doxorubicin should be considered... - Update on imaging and treatment of Ewing sarcoma family tumors: what the radiologist needs to knowWinnie A Mar
Department of Radiology, The University of Arizona College of Medicine, Tucson, AZ 85724 5067, USA
J Comput Assist Tomogr 32:108-18. 2008..This review article provides an update on multimodality imaging characteristics of Ewing sarcoma family tumors. Pathology of this tumor and current trends in medical and surgical treatment are briefly discussed... - Increased expression of the Hsp70 cochaperone HspBP1 in tumorsDeborah A Raynes
Department of Animal Sciences, University of Arizona, Tucson, AZ 85721, USA
Tumour Biol 24:281-5. 2003..These studies have shown that HspBP1 is elevated in the tumors examined and therefore could be a new cancer marker... - Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosisJuan A Gutierrez
Department of Pediatrics, Steele Memorial Children's Research Center, University of Arizona College of Medicine, Tucson, USA
Crit Care Med 31:80-3. 2003..CONCLUSIONS: This study suggests that young children with DKA have an increased incidence of clinical DVT associated with the placement of femoral central venous catheters... - Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:5410-7. 2007..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes... - A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel
University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
Clin Cancer Res 13:1789-93. 2007..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)... - NeuroblastomaJohn M Maris
Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
Lancet 369:2106-20. 2007..Finally, we discuss new approaches to treatment, including recently discovered molecular targets that might provide more effective treatment strategies with the potential for less toxicity...
Research Grants
- Hsp90 as a Target for the Treatment of Childhood CancerRochelle Bagatell; Fiscal Year: 2007..Upon completion of the award period, Dr. Bagatell will be well prepared to move forward as an independent investigator. ..